Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Manhattan Associates Inc (MANH) Price & Performance

BridgeBio Pharma IncTrade
Manhattan Associates IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Manhattan Associates Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Manhattan Associates Inc trades at $190.49 (market cap $11.41B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.

BBIOMANH
Market Cap
$16.61B$11.41B
Sector
HealthTechnology
52-Week High
$90.17$220.19
52-Week Low
$47.29$120.88
Enterprise Value
$18.16B$11.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Manhattan Associates Inc

MANH trades at $195.23, up 2.41% in the last 24 hours, with a bullish technical outlook supported by a golden cross and strong momentum indicators. The company reported Q2 2026 EPS of $1.39, beating estimates, and maintains robust profitability with an 18.67% net income margin. However, high valuation ratios like a P/E of 56.07 and ongoing legal investigations pose concerns.

Outlook is positive with an 80% analyst buy rating and a $210.33 consensus price target, implying ~8% upside. Key risks include elevated valuation multiples and fiduciary duty investigations by Rosen Law Firm, which could impact investor confidence near-term.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Manhattan Associates Inc

Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.

Read more on MANH